Summary: EnsoData has launched an RPM solution within its EnsoSleep PPG AI ecosystem, allowing clinicians to continuously track sleep apnea treatment effectiveness via wearable devices with no learning curve.
Key Takeaways:
- The RPM solution provides clinicians with ongoing AHI data, enabling proactive intervention as patients adjust to their sleep apnea therapies.
- It uses wearable devices and a mobile app already familiar to patients.
- The same device and platform used for initial diagnosis (EnsoSleep PPG) are also used for ongoing therapy monitoring.
EnsoData introduces a remote physiological monitoring (RPM) offering to the EnsoSleep PPG ecosystem of artificial intelligence (AI) tools. EnsoData’s RPM solution allows clinicians to monitor patients over time and proactively intervene when patients need support with their therapy the most.
Using only a PPG-based device, EnsoSleep PPG Study Management, and the Celeste+ mobile application, RPM provides uniform apnea-hypopnea index (AHI) monitoring across all treatment modalities, including CPAP, implantable devices, oral appliances, and GLP-1s.
EnsoSleep PPG provides diagnostic-grade AHI data that monitors treatment response longitudinally as patients adjust to sleep apnea therapy to improve outcomes beyond 3- and 12-month milestones.
“EnsoData’s RPM solution uses the same device for monitoring therapy as for testing, making it very user friendly for both patients and our team. Our patients already understand the devices and the app from testing, so there’s no learning curve,” says Ernesto Eusebio, MD, founder and medical director of the Sleep & Apnea Institute of Florida, in a release. “Plus, our sleep staff can more easily track therapy progress, spot issues early, and provide timely support, all while accessing new billing codes to generate additional revenue beyond the testing phase.”
Patients using EnsoData’s RPM solution are monitored at home using ring, watch, or patch-based devices. As patients adjust to therapy, providers can perform at-home titrations.
Sam Rusk, co-founder and chief AI officer, EnsoData, says in a release, “The natural evolution for sleep care is in remote physiological monitoring from the home. Until now, sleep medicine lacked an RPM solution that combined comfortable, wireless devices and an easily accessible physician web portal. Turning AHI into a daily vital sign empowers clinicians to manage therapy proactively to improve patient outcomes.”
